Feng Chi Biotech Corp. (TPEX:6744)

Market Cap	231.00M -26.1%
Revenue (ttm)	156.99M -12.8%
Net Income	9.91M -36.7%
EPS	0.64 -36.3%
Shares Out	15.40M
PE Ratio	23.32
Forward PE	n/a
Dividend	0.84 (5.60%)
Ex-Dividend Date	Jul 21, 2026

Volume	1
Open	15.00
Previous Close	15.00
Day's Range	15.00 - 15.00
52-Week Range	13.30 - 20.30
Beta	0.30
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Feng Chi Biotech

Feng Chi Biotech Corp. engages in the wholesale and retail of medical devices and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services, as well as infectious disease detection services. It also distributes various genetic and medical testing services. The company was founded in 1992 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 32
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6744

Financial Performance

In 2025, Feng Chi Biotech's revenue was 177.36 million, an increase of 3.66% compared to the previous year's 171.10 million. Earnings were 14.47 million, a decrease of -12.78%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error